1McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med, 1998, 338 :557-563.
2Kaplan SA. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5 alpha-reductase inhibitor dutasteride: results of 4-year studies. J Urol, 2006, 175:2211-2212.
3Maria McCrohan A, Morrissey C, O' keane C et al.Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer, 2006, 106:2743-2752.
4Lepor H,Williford WO,Barry MJ,et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med,1996, 335:533-539.
5Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia : the Prospective European Doxazosin and Combination Therap (PREDICT) trial.Urology,2003,61 : 119-126.
6McConnell JD, Roehrborn CG,Bautista OM ,et al. The long-term effect of eoxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.
7Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU International, 2005, 95:575-579.
